SCHEMBL3229048

SCHEMBL3229048

CCN(CCO)CCCCN(C)c1ccnc2cc(Cl)ccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 1/20 0.66
KCNH2 Q12809 5/20 0.63
CHRM2 P08172 3/20 0.63
CHRM1 P11229 3/20 0.63
ADRA2C P18825 3/20 0.63
CHRM4 P08173 2/20 0.63
CHRM5 P08912 2/20 0.63
ADRA2A P08913 2/20 0.63
ADRA2B P18089 2/20 0.63
CHRM3 P20309 2/20 0.63
TMEM97 Q5BJF2 2/20 0.63
SIGMAR1 Q99720 2/20 0.63
ACE2 Q9BYF1 2/20 0.63
LMNA P02545 2/20 0.63
ADRA1D P25100 1/20 0.63
CGAS Q8N884 1/20 0.63
TLR9 Q9NR96 1/20 0.63
TLR7 Q9NYK1 1/20 0.63
CYP2D6 P10635 5/20 0.52
CYP2C19 P33261 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454549 0.92 KCNH2 (0.60) CDK1KCNH2CHRM2CHRM1ADRA2C
Phosphoric Acid SCHEMBL5071916 0.88 KDM4E (0.64) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL6433202 0.87 CDK1 (0.50) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL6388962 0.87 CHKA (0.57) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL5074576 0.86 CDK1 (0.49) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL1550687 0.86 CDK1 (0.62) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL1695377 0.83 HRH3 (0.54) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL3230523 0.80 CDK1 (0.96) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL3454269 0.80 CHRM2 (0.43) CDK1KCNH2CHRM2CHRM1ADRA2C
SCHEMBL5787832 0.79 CDK1 (0.94) CDK1KCNH2CHRM2CHRM1ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694086-A1 MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE The Texas A&M University System (US) 2014-02-12 EP claimed
WO-2012138708-A1 MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-10-11 WO claimed
WO-2012135632-A2 METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-10-04 WO claimed
EP-1261340-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RES GROUP LLC (US) 2005-05-04 EP claimed
JP-2004500331-A 2004-01-08 JP claimed
EP-1261340-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE Alpha Research Group, LLC (US) 2002-12-04 EP claimed
WO-2001003649-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE ALPHA RESEARCH GROUP, LLC (US) 2001-01-18 WO claimed
WO-2026102297-A1 ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE Fulcrum Therapeutics, Inc. (US) 2026-05-15 WO disclosed
WO-2023043953-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY AVIDITY BIOSCIENCES, INC. (US) 2023-03-23 WO disclosed
EP-4126066-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY Avidity Biosciences, Inc. (US) 2023-02-08 EP disclosed
EP-4121063-A1 COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY Avidity Biosciences, Inc. (US) 2023-01-25 EP disclosed
EP-3898693-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF Avidity Biosciences, Inc. (US) 2021-10-27 EP disclosed
WO-2021195469-A1 COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY AVIDITY BIOSCIENCES, INC. (US) 2021-09-30 WO disclosed
WO-2012163814-A1 CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA INSTITUT CURIE (FR) 2012-12-06 WO disclosed
WO-2012135632-A2 METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT THE TEXAS A&M UNIVERSITY SYSTEM (US) 2012-10-04 WO disclosed
WO-2010008554-A2 METHODS AND PRODUCTS FOR TREATING PROLIFERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2010-01-21 WO disclosed
EP-1581167-A4 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS ALPHA RES GROUP LLC (US) 2008-10-29 EP disclosed
EP-1581167-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE AND TARDIVE DYSKINESIAS Alpha Research Group, LLC (US) 2005-10-05 EP disclosed
WO-2004050837-A2 TREATMENT OF DNA DAMAGE RELATED DISORDERS ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2004-06-17 WO disclosed
WO-2004004660-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON’S DISEASE AND TARDIVE DYSKINESIAS ALPHA RESEARCH GROUP, L.L.C. (US) 2004-01-15 WO disclosed